Successful management of near-infrared photoimmunotherapy-induced skin injury using pedicled flap transfer. (PubMed, Auris Nasus Larynx)
Currently, NIR-PIT is approved only in Japan for the treatment of unresectable, locally recurrent head and neck squamous cell carcinoma, using the anti-epidermal growth factor receptor antibody cetuximab and the photoabsorber IR700...After confirming the absence of tumor recurrence, the patient was successfully treated using a well-vascularized pedicled flap. This case highlights two key management considerations for NIR-PIT-induced skin injury: surgical indications and cancer treatment. Further studies are necessary to improve the management of severe skin complications following NIR-PIT.